Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a leading medical products company specializing in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration. The company's core mission is to restore peripheral nerve function and improve the quality of life for patients suffering from traumatic injuries or surgical procedures that impact nerve function and sensation.
Axogen's innovative product portfolio includes:
- Avance® Nerve Graft: The first and only commercially available allograft for bridging nerve discontinuities.
- Axoguard® Nerve Connector: A coaptation aid designed for the close approximation of severed nerves.
- Axoguard® Nerve Protector: A product that shields nerves during the healing process.
- Axoguard® Nerve Cap: A surgical implant to isolate and protect a peripheral nerve end, minimizing painful neuroma development.
- Axoguard HA+ Nerve Protector: A next-gen nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries.
- Avive® Soft Tissue Membrane: A biologically active product aiding in nerve healing.
- Axotouch® Two-Point Discriminator: An assessment tool for measuring the innervation density of skin surface areas.
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. The company continues to expand its global presence and partnerships, ensuring that healthcare providers and surgeons have access to clinically and economically effective nerve repair solutions.
Recent achievements include the launch of the Axoguard HA+ Nerve Protector, which provides enhanced nerve gliding and protection for a wide range of peripheral nerve injuries. The company reported strong performance in Q4 2023, with an expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
For more information, visit www.axogeninc.com.
Axogen, Inc. (NASDAQ: AXGN) announced that its chairman and CEO, Karen Zaderej, will present at two investor events in November 2020. The first event, the Jefferies Virtual London Healthcare Conference, is scheduled for November 18 at 3:15 p.m. (10:15 a.m. ET). The second, the Canaccord Genuity Virtual MedTech & Diagnostics Forum, will take place on November 19 at 10:00 a.m. ET. Both presentations will be available via live webcast on the company's Investors page and will be archived for 90 days.
Axogen reported a 17% increase in net revenue for Q3 2020, reaching $33.4 million, up from $28.6 million in Q3 2019. The gross margin stood at 83.0%, slightly down from 84.2% a year prior. Notably, the company narrowed its net loss to $1.5 million or $0.04 per share, significantly improving from a loss of $5.6 million or $0.14 per share year-over-year. Adjusted EBITDA was $2.3 million, a recovery from the prior year's loss. Operationally, active accounts grew by 11% to 875.
Axogen, Inc. (NASDAQ: AXGN) announced that it will report its third quarter 2020 financial results on October 29, 2020, after market close. An investment-community conference call and webcast will follow at 4:30 p.m. ET. Interested investors can join the call by phone or via a webcast on Axogen's website. The company focuses on developing innovative surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard® series.
Axogen, Inc. (NASDAQ: AXGN) appointed healthcare veteran Paul G. Thomas to its Board of Directors effective September 30, 2020. With over 30 years of medtech experience, Thomas will enhance Axogen's strategic direction, serving on the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. He previously held leadership roles at Abiomed and LifeCell Corporation. Thomas succeeds Robert J. Rudelius, who resigned after a decade of service. The company focuses on innovative surgical solutions for peripheral nerve repair, emphasizing improved quality of life for patients.
Axogen, a leader in surgical solutions for peripheral nerve damage, announced that CEO Karen Zaderej will present at the JMP Securities MedTech Bio Summit on October 1, 2020, at 11:00 a.m. ET. This virtual event will be accessible via Axogen's Investors page, with a replay available for 90 days. Axogen focuses on technologies for nerve regeneration and has a comprehensive product portfolio, including Avance® Nerve Graft and Axoguard® series, aimed at restoring nerve function and improving patient outcomes.
Axogen (NASDAQ: AXGN) will participate in the 75th Annual Meeting of the American Society for Surgery of the Hand from October 1-3, 2020. Key presentations will highlight the clinical and economic benefits of Avance Nerve Graft compared to traditional nerve autografts. Clinical data from the RANGER® Registry shows comparable outcomes for sensory and motor nerve injuries. Additionally, a cost evaluation confirms Avance's procedural costs are competitive. Axogen will also host a virtual symposium, Nerve Repair Live, on September 29, featuring live surgical demonstrations.
Axogen (NASDAQ: AXGN) announced that Karen Zaderej, chairman, CEO, and president, will present at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 1:20 p.m. ET. The presentation will be available via live webcast on the company's Investors page.
Axogen is a leader in developing surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard® Nerve Protector to enhance recovery and improve patients' quality of life.
Axogen, a leader in surgical solutions for peripheral nerve repair, announced that CEO Karen Zaderej will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 9:00 a.m. ET. The presentation will be available via live webcast on Axogen's investor page, with a replay accessible for 90 days. Axogen specializes in innovative technologies for nerve regeneration, offering a range of products including Avance Nerve Graft and Axoguard products to assist in nerve repair and protection. The company is committed to improving patient outcomes in nerve function restoration.
Axogen, Inc. (NASDAQ: AXGN) will release its second quarter 2020 financial results on August 5, 2020, post-market. The company's management will hold a conference call and webcast at 4:30 p.m. ET to discuss these results. Axogen is recognized for its innovative surgical solutions for peripheral nerve damage, including its portfolio of products like Avance® Nerve Graft and Axoguard® series. Investors can join the call by phone or through the company's website. A replay will be available after the call.
Axogen, Inc. (NASDAQ: AXGN) announced a financing agreement with Oberland Capital, allowing for up to $75 million in tranches. The first tranche of $35 million was drawn on June 30, 2020. Preliminary revenue for Q2 2020 is estimated at $21 million, down 21% from the previous year. The financing will support expansion, including a new biologic processing center. The CEO noted a regional recovery in nerve repair procedures but cautioned that COVID-19 continues to impact surgical volume, leading to a cautious revenue outlook for the remainder of the year.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
What is Axogen, Inc. focused on?
What are some key products offered by Axogen?
In which markets are Axogen's products available?
What recent product did Axogen launch?
What is the Avance® Nerve Graft?
How did Axogen perform financially in Q4 2023?
What does the Axoguard® Nerve Cap do?
What is the function of the Axotouch® Two-Point Discriminator?
Who is the current CEO of Axogen?
Where can I find more information about Axogen?
